enGene Therapeutics Inc. (ENGN) stock
ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
$2.41+0.13 (+5.70%)
Close on Nov 13, 2026Market cap $161.51MP/E –Yield 0.00%
enGene Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
enGene Therapeutics's total debt was $25.16M at Jul 31, 2026. For fiscal 2025 it was $15.32M, down 31.8% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $15.32M | -31.8% |
| FY2024 | Oct 31, 2024 | $22.47M | +143.8% |
| FY2023 | Oct 31, 2023 | $9.22M | -4.5% |
| FY2022 | Oct 31, 2022 | $9.65M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | $25.16M | +42.1% |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | $24.91M | +24.4% |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | $24.74M | +14.0% |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | $15.32M | -31.8% |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | $17.71M | -18.1% |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | $20.02M | -11.9% |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | $21.70M | -3.7% |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | $22.47M | +143.8% |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | $21.61M | +124.0% |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | $22.73M | – |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | $22.53M | – |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | $9.22M | – |
| Q4 FY2022CQ3 2022 | Oct 31, 2022 | $9.65M | – |
See a number that looks wrong?